Home/Filings/4/0001104659-21-093666
4//SEC Filing

Kaufman Michael J. 4

Accession 0001104659-21-093666

CIK 0001442836other

Filed

Jul 18, 8:00 PM ET

Accepted

Jul 19, 8:50 PM ET

Size

11.7 KB

Accession

0001104659-21-093666

Insider Transaction Report

Form 4
Period: 2021-07-15
Kaufman Michael J.
Sr VP Chmistry, Man & Control
Transactions
  • Exercise/Conversion

    Common Stock

    2021-07-15+40,00044,710 total
  • Sale

    Common Stock

    2021-07-19$12.02/sh6,312$75,87032,622 total
  • Sale

    Common Stock

    2021-07-16$12.47/sh5,776$72,02738,934 total
  • Exercise/Conversion

    Restricted Stock Units

    2021-07-1540,0000 total
    Common Stock (40,000 underlying)
Footnotes (5)
  • [F1]Each restricted stock unit ("RSU") listed in Table II represented a contingent right to receive one share of the Issuer's common stock upon vesting.
  • [F2]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the reporting person
  • [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.27 to $12.61, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  • [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.90 to $12.23, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
  • [F5]The RSUs vested in their entirety on July 15, 2021.

Issuer

Mersana Therapeutics, Inc.

CIK 0001442836

Entity typeother

Related Parties

1
  • filerCIK 0001709996

Filing Metadata

Form type
4
Filed
Jul 18, 8:00 PM ET
Accepted
Jul 19, 8:50 PM ET
Size
11.7 KB